Casper Pharma gets 2 USFDA observations

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-07-15T14:17:20+05:30 | Updated On 15 July 2024 2:17 PM IST

Alembic Pharma gets USFDA EIR for Panelav facility

Maharashtra: Suven Pharma has announced that the United States Food & Drug Administration (US FDA) has completed the surveillance inspection of Casper Pharma Private Limited in Hyderabad, a WOS of the company with two observations.

The inspection took place from July 8, 2024, to July 12, 2024.

"The Company has been issued a Form 483 with two observations, which are procedural in nature. We are committed to addressing these observations within the stipulated timeline," Suven Pharma stated.

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

suven pharmasuven pharma newsUSFDAUSFDA inspectionCasper Pharma

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751